Lori A. Leslie, MD: Though we have made dramatic improvements in the treatment options available for patients with various lymphoma subtypes over the last few years, we still have much work ahead. I think patient selection is very important. We’re working on how to optimally risk stratify patients on an individual level to determine the best treatment for the specific factors driving each case. We also must identify patients having suboptimal responses to therapy earlier to be able to shift gears, perhaps via consolidative treatments after frontline chemoimmunotherapy or post-CAR T-cell therapy for those not achieving deep molecular remissions. Doing so can facilitate the continued evolution of lymphoma care toward providing curative intent options for all patients.

Thank you for joining me for this informative discussion. We hope you found this OncLive Peer Exchange discussion useful and valuable for treating your patients.

Transcript edited for clarity.